CT panel OKs one more condition for medical marijuana program
February 26, 2018
Connecticut’s Board of Physicians on Monday added one medical condition that can be treated through the state’s medical marijuana program.
Following a morning public hearing, the board approved medical marijuana use osteogenesis imperfecta, but did not recommend approval for albinism, also known as nystagmus.
Albinism is a congenital disorder in which a person has complete or partial absence of pigment in the skin, hair and eyes. In the genetic disorder osteogenesis imperfecta, bones break easily.
Up until Monday’s vote, there were 22 conditions that may qualify adults for Connecticut’s medical marijuana program, and six conditions for patients under 18.
For two additional conditions, the board decided to table action and hold another public hearing to be scheduled at a future date.
For the conditions of opioid use disorder/opiate withdrawal, the board is “looking for more input from the addiction and mental health communities,” said state Department of Consumer Protection spokesperson Lora Rae Anderson. The board also wants to better define the condition of progressive degenerative disc disease of the spine, she said.
To submit information or feedback to the board, email board members at [email protected]
There are currently 23,889 medical marijuana patients in the state and 834 physicians registered with the program.
CORRECTION: A previous version of this story incorrectly stated that the board had recommended albinism for approval.